BRITISH medical scheme
manager NHS England has received
guidance from the National
Institute for Health and Care
Excellence (NICE) around the use of
Kadcyla (trastuzumab-emtansine).
NICE has declared the HER2-
positive breast cancer therapy too
expensive at £90,000 per patient at
its full list price for routine use on
the NHS.
People currently taking Kadcyla
will not stop receiving it said NICE.
They have the option to continue
treatment until they and their
doctors consider it appropriate to
stop.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Dec 15
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.